This article has Open Peer Review reports available.
A mild form of dermatomyositis as a prodromal sign of lung adenocarcinoma: a case report
© Papakonstantinou et al. 2016
Received: 9 October 2015
Accepted: 21 January 2016
Published: 6 February 2016
Dermatomyositis is an idiopathic connective tissue disease characterized by specific cutaneous findings and inflammatory lesions in the muscle biopsy. An association between dermatomyositis and malignancy, including breast, ovarian, lung and colon cancer was recognized many years ago, with an incidence of malignancy in approximately 20 % of cases. Dermatomyositis is hypothesized to be an autoimmune reaction against factors or hormones secreted by the tumor; however, the exact autoimmune mechanism of the disease pathogenesis remains unknown.
Here we report a case of a woman with dermatomyositis who was diagnosed with lung adenocarcinoma in the setting of weight loss, progressive fatigue and muscle weakness. A 43-year-old Caucasian woman was referred to our hospital by her physician for suspected contact dermatitis since she described mild itching sensations in her arms and legs as her major symptom. A physical examination revealed erythematous papular lesions over her metacarpophalangeal and proximal interphalangeal joints together with a periungual involvement with redness, hyperkeratosis and capillary telangiectasia along the distal nailfolds on her hands. She was unaware of these features and they did not seem to bother her. A thorough examination of her medical history, however, revealed more symptoms. Pain and weakness in the muscles of her proximal extremities and neck flexor muscles led to difficulty in raising her arms and climbing stairs. At the same time she experienced swallowing difficulties and reported an uncharacteristic weight loss of 10 kg in the last 3 months. The results of laboratory tests showed increased values of serum creatine kinase and myoglobin. An electromyogram, a skin biopsy and a muscle biopsy confirmed the diagnosis of dermatomyositis. A computed tomography of her thorax showed a nodular mass in the upper lobe of her right lung. A histological examination of the lung biopsy showed an adenocarcinoma of moderate differentiation. She was diagnosed with paraneoplastic dermatomyositis as the first sign of a lung adenocarcinoma.
Our case report highlights the importance of a thorough search for underlying malignancy in patients with dermatomyositis even if dermatomyositis has a mild appearance or a discrete skin manifestation.
Dermatomyositis is an idiopathic inflammatory disease that is caused by an autoimmune reaction against skin and muscles. Viral infections, drugs or malignancy are the most commonly suggested trigger factors that may lead to an immune response. Dermatomyositis has typical cutaneous features and can appear with or without an inflammatory myositis.
The most common skin manifestations are an erythema over the face, neck, and upper trunk known as “neckline V sign” and slightly elevated erythematous papules located on the metacarpophalangeal and proximal interphalangeal joints, called “Gottron’s papules” which are found in 60 to 80 % of patients. A purple-red discoloration of the upper eyelids with or without associated eyelid edema may be present. Nail changes such as capillary telangiectasia along the distal nailfold, periungual erythema, and hyperkeratosis are common and, although usually ignored by the patients, can be a prodromal sign of dermatomyositis. More rarely calcinosis or hyperkeratotic lesions on the fingers known as “Mechanic’s hand” appear.
Other cutaneous symptoms include photosensitivity and pruritus . The muscle symptoms consist of mild to severe weakness of the proximal muscles, followed by pain in one third of cases. These patients have difficulties raising their arms or climbing stairs. Muscle cramps and diffuse unexplained fatigue may be present as well. Dysphagia, weight loss, or dyspnea may appear over time and are usually signs of disease progression or underlying malignancy. The clinical presentation of dermatomyositis and the severity of clinical symptoms vary from patient to patient. There is no specific sequence of the symptoms and not all of them have to be present in order for the diagnosis to be verified. Dermatomyositis may also have atypical manifestations or appear in an incomplete form.
She complained about pain and weakness in the muscles of her proximal extremities and neck flexor muscles with difficulty raising her arms and climbing stairs. At the same time she experienced swallowing difficulties and reported an uncharacteristic weight loss of 10 kg in the last 3 months. She had a 30 pack-year history of cigarette smoking with persistent nicotine use at the time of presentation in our clinic. A neurological examination showed symmetrical mild proximal muscle weakness. The rest of her physical examination including auscultation of her lungs, body temperature and lymph nodes status was normal.
She was given a presumed diagnosis of a lung adenocarcinoma with clinical manifestations of paraneoplastic dermatomyositis. No metastatic lesions were found, and there were no abdominal or cerebral abnormalities. A corticosteroid treatment with prednisolone 1 mg/kg/day was administered. In the absence of cardiologic or anesthesiologic contraindications she was assessed to be eligible for surgery. She underwent a right upper lobectomy. The histopathology showed a moderately differentiated adenocarcinoma that was pathologically staged as T1b N0 M0. In the postoperative period, she presented partial improvement of her skin lesions, muscle weakness and dysphagia.
Dermatomyositis is an idiopathic inflammatory disease which affects muscles and skin and is characterized by skin rash and inflammation. Skin manifestations include erythema over the face, neck and upper trunk known as “neckline V sign”, erythema on the extensor surface of extremity joints, erythematous papules located on the metacarpophalangeal and proximal interphalangeal joints, called “Gottron’s papules” or purple-red discoloration of the upper eyelids usually associated with eyelid edema “heliotrope sign”. Typical nail disorders include capillary telangiectasia along the distal nailfolds and periungual erythema. Photosensitivity and pruritus have also been described in patients with dermatomyositis. Creatine kinase elevation, abnormalities in an electromyogram and inflammatory lesions in skin and muscle biopsy are typical findings . The hallmarks of classic dermatomyositis include skin manifestations, proximal muscle weakness and laboratory data showing muscle inflammation. The entity dermatomyositis sine myositis has already been described and is known as amyopathic dermatomyositis. It is thought to concern approximately 20 % of patients with dermatomyositis  and is associated with a risk for rapidly progressive fatal interstitial lung disease . However, the entity dermatomyositis sine dermatitis has rarely been reported and little literature exists to support this variant .
Our patient was admitted to our clinic of dermatology for exclusion of contact allergy by her physician, because of an itching sensation involving her arms and legs. A thorough physical examination revealed light elevated erythematous papular lesions over her metacarpophalangeal and proximal interphalangeal joints and nail changes such as periungual erythema and capillary telangiectasia along the distal nailfolds on both hands, which were of no subjective clinical significance for our patient. Other typical clinical features of dermatomyositis such as heliotrope rash or erythema on the extensor surface of extremity joints were absent. Since respective clinical signs raised a suspicion of dermatomyositis we intensified our examination which additionally revealed pain and proximal muscle weakness, swallowing difficulties and an uncharacteristic weight loss of 10 kg in the last 3 months. As a sudden presentation of dermatomyositis may be of paraneoplastic origin we performed further testing in order to exclude malignancy.
An association between dermatomyositis and malignancy was described many years ago. Approximately 15 to 20 % of adult patients with dermatomyositis present with cancer at the time of the diagnosis or at some point during the follow-up . Chow et al.  suggested that the risk of malignancy is higher in the first year after the diagnosis of dermatomyositis and reduces gradually over the following years. Chen et al.  showed that the risk of malignancy in patients with dermatomyositis is higher during the first 5 years after the diagnosis. Compared to the risk of malignancy in the general population, the increased risk of malignancy in patients with dermatomyositis remains higher through all years of follow-up [7, 8]. In a retrospective analysis of 618 patients with dermatomyositis, 198 (32 % of the patients) had cancer. In 115 cases (19 % of the patients) malignancy was found after the diagnosis of dermatomyositis. In 83 cases (13 % of the patients) dermatomyositis and cancer were diagnosed concomitantly. A similar correlation was shown by Fujita et al.  concerning lung cancer. Despite the fact that a majority of malignancies are diagnosed after dermatomyositis, the tumor may be diagnosed before or at the same time as the dermatomyositis, as in our case.
The most common types of cancer associated with paraneoplastic dermatomyositis are ovary, lung, pancreatic, stomach, colorectal cancer or non-Hodgkin lymphoma with a prevalence of 6 to 45 % of patients . Among them, ovary cancer has the highest incidence worldwide [10, 11]. For all types of cancer, however, the risk of malignancy after a diagnosis of dermatomyositis is increased three times .
Although the pathogenetic mechanism of dermatomyositis related to underlying malignancy remains unclear, there are some hypotheses which suggest the manifestation of dermatomyositis as a result of an immune disorder, an immunologic response, a substance secretion by neoplastic cells or as a response to newly presented tumor-associated antigens. The symptoms of dermatomyositis vary in severity and number and usually precede the diagnosis of malignancy.
Sterzt reported a paraneoplastic dermatomyositis with coexisting stomach cancer for the first time in 1916 and Kankeleit described a correlation with breast cancer at the same time. Andreev  showed that dermatomyositis often coexists with lung cancer some years later, although only a few reports are available to confirm this statement.
Lung cancer can be divided into two categories: small cell carcinoma and non-small cell carcinoma with diverse clinical manifestations depending on the localization, the infiltration of co-structures, the metastases and the paraneoplastic manifestations. On histological examination, it can be classified in four categories: squamous cell carcinoma, adenocarcinoma, large cell carcinoma and small cell carcinoma . Hypertrophic osteopathy has been described as the most common paraneoplastic syndrome associated with lung cancer .
There are data that suggest that the presence of dermatomyositis is a paraneoplastic manifestation of lung cancer. However, a coexistence with a lung adenocarcinoma is rather rare. Paraneoplastic dermatomyositis has a higher incidence in cases of small cell carcinoma, followed by squamous cell carcinoma and adenocarcinoma . Among the four histological types of lung cancer, adenocarcinoma is the one most commonly found in non-tobacco smokers and women. It is characterized by its peripheral location and a worse prognosis caused by the early appearance of metastases .
Our patient, however, was a woman who was a cigarette smoker which differs from the abovementioned data given from the literature. She had an unusual manifestation of a lung adenocarcinoma with a mild dermatomyositis as a prodromal sign of her tumor disease. Fortunately, because of the early diagnosis of cancer, she had no metastases. Her paraneoplastic dermatomyositis presented in a rather mild form. Her papular lesions and nail disorders were the only typical signs in such a mild form and she was unaware of them. Other typical skin manifestations such as heliotropic rash and erythema of the upper trunk, neck and arms were absent. In this case report we showed that even if the complete clinical image of classic dermatomyositis is not present there is a high risk of an underlying malignancy.
Our patient additionally complained about persisting pruritus as her major symptom leading to her initial consultation with her physician before coming to our clinic. Although pruritus has already been described as a clinical feature of dermatomyositis it remains a low-yield symptom concerning the diagnosis and is rather underestimated . Dundley et al.  showed that pruritus can severely affect the quality of life of patients with dermatomyositis. In our case report it is remarkable that our patient described pruritus as one of her major symptoms, when asked. Therefore, the management of pruritus may also be included in the therapeutical concept in dermatomyositis.
As the pathophysiology of paraneoplastic dermatomyositis remains unclear, no standard treatment regimen has been established yet. Therapy with high-dose corticosteroids is suggested as the first-line therapy. In patients with no therapeutical response to corticosteroids an immunosuppressive therapy with azathioprine, cyclosporine, mycophenolate or methotrexate may lead to an improvement of symptoms and better disease control. Therapy with human immunoglobulins administered intravenously (IVIG) is suggested as second-line therapy . In any case, the control of the underlying malignancy is independent of the severity of dermatomyositis and remains the most important part of the therapy as dermatomyositis improves or resolves after cancer treatment. As patients with a tumor and dermatomyositis may have a worse prognosis and quality of life, early diagnosis and treatment of this paraneoplastic disease is highly important.
Our case report illustrates that paraneoplastic dermatomyositis, even in a mild form without all of the typical skin manifestations, may appear as a prodromal sign of malignancy. As the prognosis of paraneoplastic dermatomyositis depends on the underlying malignancy, an early recognition and awareness of this entity is not only important for a prompt diagnosis of the tumor but also for a better prognosis and quality of life for these patients.
Written informed consent was obtained from the patient for publication of this case report and accompanying images. A copy of the written consent is available for review by the Editor-in-Chief of this journal.
We kindly thank Ms S. Kleiner (New York, USA) for proofreading.
Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
- Kovacs SO, Kovacs SC. Dermatomyositis. J Am Acad Dermatol. 1998;39:899–920.View ArticlePubMedGoogle Scholar
- Dourmishev AL, Schwartz RA. Dermatomyositis: cutaneous manifestations of its variants. Int J Dermatol. 2002;41(10):625–30.View ArticlePubMedGoogle Scholar
- Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146:26–30.View ArticlePubMedGoogle Scholar
- Kang EH, Lee EB, Shin KC, Im CH, Chung DH, Han SK, et al. Interstitial lung disease in patients with polymyositis, dermatomyositis and amyopathic dermatomyositis. Rheumatology. 2005;44:1282–6.View ArticlePubMedGoogle Scholar
- Leteurtre E, Hachulla E, Janin A, Hatron PY, Brouillard M, Devulder B. Vascular manifestations of dermatomyositis and polymyositis. Clinical, capillaroscopic and histological aspects. Rev Med Interne. 1994;15:800–7.View ArticlePubMedGoogle Scholar
- So MW, Koo BS. Idiopathic inflammatory myopathy associated with malignancy: a retrospective cohort of 151 Korean patients with dermatomyositis and polymyositis. J Rheumatol. 2011;38(11):2432–5.View ArticlePubMedGoogle Scholar
- Chow WH, Gridley G, Mellemkjaer L, Mclaughlin JK, Olsen JH, Fraumeni Jr JF. Cancer risk following polymyositis and dermatomyositis: a nationwide cohort study in Denmark. Cancer Causes Control. 1995;6:9–13.View ArticlePubMedGoogle Scholar
- Chen YJ, Wu CY, Huang YL, Wang CB, Shen JL, Chang YT. Cancer risks of dermatomyositis and polymyositis: a nationwide cohort study in Taiwan. Arthritis Res Ther. 2010;12:R70.PubMed CentralView ArticlePubMedGoogle Scholar
- Fujita J, Tokuda M, Bandoh S, Yang Y, Fukunaga Y, Hojo S, et al. Primary lung cancer associated with polymyositis/dermatomyositis, with a review of the literature. Reumatol Int. 2001;20:81–4.View ArticleGoogle Scholar
- Hill CL, Zhang Y, Sigurgeirsson B, Pukkala E, Mellemkjaer L, Airio A, et al. Frequency of specific cancer types in dermatomyositis and polymyositis: a population-based study. Lancet. 2001;357:96–100.View ArticlePubMedGoogle Scholar
- Zhang W, Jiang SP. Dermatomyositis and malignancy: a retrospective study of 115 cases. Eur Rev Med Pharmacol Sci. 2009;13(2):77–80.PubMedGoogle Scholar
- Andreev VC. Skin manifestations in visceral cancer. Curr Probl Dermatol. 1978;8:1–168.View ArticlePubMedGoogle Scholar
- Koler RA, Montemarano A. Dermatomyositis. Am Fam Phys. 2001;64(9):1565–72.Google Scholar
- Collins LG, Haines C, Perkel R, Enck RE. Lung cancer: diagnosis and management. Am Fam Phys. 2007;75(1):56–63.View ArticleGoogle Scholar
- Hoffman PC, Mauer AM, Vokes EE. Lung cancer. Lancet. 2000;355(9202):479–85.View ArticlePubMedGoogle Scholar
- Shirani Z, Kucenic MJ, Carroll CL, Fleischer Jr AB, Feldman SR, Yosipovitch G, et al. Pruritus in adult dermatomyositis. Clin Exp Dermatol. 2004;29:273–6.View ArticlePubMedGoogle Scholar
- Dundley JL, Carroll CL, Lang W, Snively B, Yosipovitch G, Feldman SR, et al. Cutaneous symptoms of dermatomyositis significantly impact patients' quality of life. J Am Acad Dermatol. 2006;54:217–20.View ArticleGoogle Scholar
- Sampson JB, Smith SM, Smith AG, Singleton JR, Chin S, Pestronk A, et al. Paraneoplastic myopathy: response to intravenous immunoglobulin. Neuromuscul Disord. 2007;17:404–8.View ArticlePubMedGoogle Scholar